Medicine
Glyxambi 25 mg/5 mg tablet
Glyxambi 25 mg/5 mg tablet is a prescription medicine containing Empagliflozin and Linagliptin for oral use, marketed by Boehringer Ingelheim Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C…
Key facts
- Active ingredient (INN)
- Empagliflozin and Linagliptin
- Brand
- Glyxambi
- Strength
- 25 mg/5 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 30 tablets, 30 blister pack, 90 tablets
- Marketing authorisation holder
- Boehringer Ingelheim Pharmaceuticals
- Manufacturer
- Boehringer Ingelheim Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- A10BD19 Empagliflozin and Linagliptin
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 30 January 2015
- Identifiers
- RxCUI 1602109, 1602115, 1602118 +1DailyMed set ID ddbab689-f76c-488c-9613-4168d41dd730NDC 0597-0164Application NDA206073
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 30 tablet, film coated in 1 bottle | 0597-0164-30 | Boehringer Ingelheim Pharmaceuticals | 30 January 2015 |
| 30 blister pack in 1 carton / 1 tablet, film coated in 1 blister pack | 0597-0164-39 | Boehringer Ingelheim Pharmaceuticals | 30 January 2015 |
| 90 tablet, film coated in 1 bottle | 0597-0164-90 | Boehringer Ingelheim Pharmaceuticals | 30 January 2015 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Empagliflozin and Linagliptin
Clinical summary
Empagliflozin and Linagliptin is a fixed-dose combination of a dipeptidyl peptidase 4 inhibitor and a sodium-glucose cotransporter 2 inhibitor. It is available as tablets for oral use. MedsAcross supplies Empagliflozin and Linagliptin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Empagliflozin and LinagliptinFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Glyxambi prescribing information (Boehringer Ingelheim Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Glyxambi: European public assessment report (EPAR) · European Medicines Agency
Need Glyxambi 25 mg/5 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.